Tags

Type your tag names separated by a space and hit enter

[Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl].
Fortschr Med. 1979 May 17; 97(19):926-8.FM

Abstract

In a multicentre study a total of 113 patients suffering from disturbed blood flow conditions of the lower extremities (type II Fontaine) were treated with butalamine hydrochloride tablets, each containing 80 mg of the active principle. In 96% of the cases given a daily dose of 3 x 2 tablets and in 82% of those treated with a daily dose of 3 x 1 tablet both subjective and objective clinical symptoms, such as walking distance and Ratschow's testing parameters, were found to be improved. In view of the findings that metabolic functions as well as systemic blood flow conditions were not affected and that the drug was furthermore well tolerated by the gastrointestinal system, butalamine hydrochloride proved to be an effective therapeutic in long-term treatment of patients suffering from blood flow disorders of the lower extremities.

Authors

No affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
English Abstract
Journal Article

Language

ger

PubMed ID

109382

Citation

Kling, H. "[Drug Therapy of Chronic Arterial Occlusive Diseases of the Lower Extremities With Butalamine-HCl]." Fortschritte Der Medizin, vol. 97, no. 19, 1979, pp. 926-8.
Kling H. [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl]. Fortschr Med. 1979;97(19):926-8.
Kling, H. (1979). [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl]. Fortschritte Der Medizin, 97(19), 926-8.
Kling H. [Drug Therapy of Chronic Arterial Occlusive Diseases of the Lower Extremities With Butalamine-HCl]. Fortschr Med. 1979 May 17;97(19):926-8. PubMed PMID: 109382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl]. A1 - Kling,H, PY - 1979/5/17/pubmed PY - 1979/5/17/medline PY - 1979/5/17/entrez SP - 926 EP - 8 JF - Fortschritte der Medizin JO - Fortschr. Med. VL - 97 IS - 19 N2 - In a multicentre study a total of 113 patients suffering from disturbed blood flow conditions of the lower extremities (type II Fontaine) were treated with butalamine hydrochloride tablets, each containing 80 mg of the active principle. In 96% of the cases given a daily dose of 3 x 2 tablets and in 82% of those treated with a daily dose of 3 x 1 tablet both subjective and objective clinical symptoms, such as walking distance and Ratschow's testing parameters, were found to be improved. In view of the findings that metabolic functions as well as systemic blood flow conditions were not affected and that the drug was furthermore well tolerated by the gastrointestinal system, butalamine hydrochloride proved to be an effective therapeutic in long-term treatment of patients suffering from blood flow disorders of the lower extremities. SN - 0015-8178 UR - https://www.unboundmedicine.com/medline/citation/109382/[Drug_therapy_of_chronic_arterial_occlusive_diseases_of_the_lower_extremities_with_butalamine_HCl]_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.